BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Jelkmann W. Biosimilar epoetins and other "follow-on" biologics: update on the European experiences. Am J Hematol 2010;85:771-80. [PMID: 20706990 DOI: 10.1002/ajh.21805] [Cited by in Crossref: 69] [Cited by in F6Publishing: 59] [Article Influence: 5.8] [Reference Citation Analysis]
Number Citing Articles
1 Lee JS, Ha TK, Lee SJ, Lee GM. Current state and perspectives on erythropoietin production. Appl Microbiol Biotechnol 2012;95:1405-16. [DOI: 10.1007/s00253-012-4291-x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 2.0] [Reference Citation Analysis]
2 Yuen C, Zhou Y, Wang Q, Hou J, Bristow A, Wang J. Glycan analysis of glycoprotein pharmaceuticals: Evaluation of analytical approaches to Z number determination in pharmaceutical erythropoietin products. Biologicals 2011;39:396-403. [DOI: 10.1016/j.biologicals.2011.08.012] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
3 Martinusen DJ, Lo C, Marin JG, Tsao NW, Leung M. Potential impact of subsequent entry biologics in nephrology practice in Canada. Can J Kidney Health Dis 2014;1:32. [PMID: 25780621 DOI: 10.1186/s40697-014-0032-7] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
4 Szekrényes Á, Partyka J, Varadi C, Krenkova J, Foret F, Guttman A. Sample preparation for N-glycosylation analysis of therapeutic monoclonal antibodies by electrophoresis. Methods Mol Biol 2015;1274:183-95. [PMID: 25673493 DOI: 10.1007/978-1-4939-2353-3_16] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
5 Cortinovis D, Beretta G, Piazza E, Luchena G, Aglione S, Bertolini A, Buzzoni R, Cabiddu M, Carnaghi C, Danova M, Farina G, Ferrari V, Frascaroli M, Reni M, Tansini G; on behalf of AIOM Lombardia. Chemotherapy-Induced Anemia and Oncologist Perception on Treatment: Results of a Web-Based Survey. Tumori 2013;99:45-50. [DOI: 10.1177/030089161309900108] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
6 Colbert RA, Cronstein BN. Biosimilars: the debate continues. Arthritis Rheum 2011;63:2848-50. [PMID: 21702015 DOI: 10.1002/art.30505] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 2.7] [Reference Citation Analysis]
7 Debeljak N, Sytkowski AJ. Erythropoietin and erythropoiesis stimulating agents. Drug Test Anal 2012;4:805-12. [PMID: 22508651 DOI: 10.1002/dta.1341] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 1.8] [Reference Citation Analysis]
8 Di Paolo A, Arrigoni E. Generic Substitution of Orphan Drugs for the Treatment of Rare Diseases: Exploring the Potential Challenges. Drugs 2018;78:399-410. [PMID: 29464665 DOI: 10.1007/s40265-018-0882-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
9 Cowper B, Li X, Yu L, Zhou Y, Fan WH, Rao CM. Comprehensive glycan analysis of twelve recombinant human erythropoietin preparations from manufacturers in China and Japan. J Pharm Biomed Anal 2018;153:214-20. [PMID: 29502007 DOI: 10.1016/j.jpba.2018.02.043] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
10 Aapro M, Jelkmann W, Constantinescu SN, Leyland-Jones B. Effects of erythropoietin receptors and erythropoiesis-stimulating agents on disease progression in cancer. Br J Cancer 2012;106:1249-58. [PMID: 22395661 DOI: 10.1038/bjc.2012.42] [Cited by in Crossref: 74] [Cited by in F6Publishing: 60] [Article Influence: 7.4] [Reference Citation Analysis]
11 Jelkmann W. Physiology and pharmacology of erythropoietin. Transfus Med Hemother 2013;40:302-9. [PMID: 24273483 DOI: 10.1159/000356193] [Cited by in Crossref: 115] [Cited by in F6Publishing: 96] [Article Influence: 12.8] [Reference Citation Analysis]
12 Hirsch BR, Lyman GH. Economics of the Recombinant Human Granulocyte Colony-Stimulating Factors. In: Molineux G, Foote M, Arvedson T, editors. Twenty Years of G-CSF. Basel: Springer; 2012. pp. 409-20. [DOI: 10.1007/978-3-0348-0218-5_22] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
13 Mikhail A, Farouk M. Epoetin biosimilars in Europe: five years on. Adv Ther 2013;30:28-40. [PMID: 23242745 DOI: 10.1007/s12325-012-0072-2] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 2.9] [Reference Citation Analysis]
14 Inotai A, Prins CPJ, Csanádi M, Vitezic D, Codreanu C, Kaló Z. Is there a reason for concern or is it just hype? - A systematic literature review of the clinical consequences of switching from originator biologics to biosimilars. Expert Opin Biol Ther 2017;17:915-26. [PMID: 28650704 DOI: 10.1080/14712598.2017.1341486] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 5.4] [Reference Citation Analysis]
15 Lee SM, Kim HJ, Suh D, Joung KI, Kim ES, Back HJ, Kwon JY, Park MJ, Suh DC. Use of budget savings from patent expiration of cancer drugs to improve affordability and accessibility. BMC Health Serv Res 2021;21:126. [PMID: 33549099 DOI: 10.1186/s12913-021-06130-y] [Reference Citation Analysis]
16 Jackisch C, Scappaticci FA, Heinzmann D, Bisordi F, Schreitmüller T, Minckwitz GV, Cortés J. Neoadjuvant breast cancer treatment as a sensitive setting for trastuzumab biosimilar development and extrapolation. Future Oncology 2015;11:61-71. [DOI: 10.2217/fon.14.187] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 4.0] [Reference Citation Analysis]
17 Gámez-Belmonte R, Hernández-Chirlaque C, Arredondo-Amador M, Aranda CJ, González R, Martínez-Augustin O, Sánchez de Medina F. Biosimilars: Concepts and controversies. Pharmacol Res 2018;133:251-64. [PMID: 29428205 DOI: 10.1016/j.phrs.2018.01.024] [Cited by in Crossref: 19] [Cited by in F6Publishing: 11] [Article Influence: 4.8] [Reference Citation Analysis]
18 Eleryan MG, Akhiyat S, Rengifo-Pardo M, Ehrlich A. Biosimilars: potential implications for clinicians. Clin Cosmet Investig Dermatol 2016;9:135-42. [PMID: 27382321 DOI: 10.2147/CCID.S91691] [Cited by in Crossref: 15] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
19 Weise M, Bielsky M, De Smet K, Ehmann F, Ekman N, Giezen TJ, Gravanis I, Heim H, Heinonen E, Ho K, Moreau A, Narayanan G, Kruse NA, Reichmann G, Thorpe R, van Aerts L, Vleminckx C, Wadhwa M, Schneider CK. Biosimilars: what clinicians should know. Blood 2012;120:5111-7. [DOI: 10.1182/blood-2012-04-425744] [Cited by in Crossref: 226] [Cited by in F6Publishing: 187] [Article Influence: 22.6] [Reference Citation Analysis]
20 Wish JB. The approval process for biosimilar erythropoiesis-stimulating agents. Clin J Am Soc Nephrol 2014;9:1645-51. [PMID: 24970875 DOI: 10.2215/CJN.01770214] [Cited by in Crossref: 12] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
21 Russell AS, Ahluwalla V, Barnabe C, Jamal S, Offer RC, Olszynski WP, Shojania K, Haraoui B. Subsequent entry biologics/biosimilars: a viewpoint from Canada. Clin Rheumatol 2012;31:1289-92. [DOI: 10.1007/s10067-012-2066-5] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
22 Park DI. Current status of biosimilars in the treatment of inflammatory bowel diseases. Intest Res. 2016;14:15-20. [PMID: 26884730 DOI: 10.5217/ir.2016.14.1.15] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
23 Hirsch BR, Lyman GH. Pharmacoeconomics of the Myeloid Growth Factors: A Critical and Systematic Review. PharmacoEconomics 2012;30:497-511. [DOI: 10.2165/11590130-000000000-00000] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
24 Ebbers HC, Pieters T, Leufkens HG, Schellekens H. Effective pharmaceutical regulation needs alignment with doctors. Drug Discovery Today 2012;17:100-3. [DOI: 10.1016/j.drudis.2011.09.018] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
25 Lee SM, Jung JH, Suh D, Jung YS, Yoo SL, Kim DW, Kim JA, Suh DC. Budget Impact of Switching to Biosimilar Trastuzumab (CT-P6) for the Treatment of Breast Cancer and Gastric Cancer in 28 European Countries. BioDrugs 2019;33:423-36. [PMID: 31201616 DOI: 10.1007/s40259-019-00359-0] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 4.3] [Reference Citation Analysis]
26 Schmid H. Peginesatide for the treatment of renal disease-induced anemia. Expert Opin Pharmacother 2013;14:937-48. [PMID: 23506424 DOI: 10.1517/14656566.2013.780695] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
27 Jez J, Castilho A, Grass J, Vorauer-Uhl K, Sterovsky T, Altmann F, Steinkellner H. Expression of functionally active sialylated human erythropoietin in plants. Biotechnol J 2013;8:371-82. [PMID: 23325672 DOI: 10.1002/biot.201200363] [Cited by in Crossref: 34] [Cited by in F6Publishing: 30] [Article Influence: 3.8] [Reference Citation Analysis]
28 Jankowska E, Cipollo J. Platform for analysis of anthranilic acid N-glycan derivatives utilizing multipolarity mode LC-MS with hydrophilic interaction chromatography separation and ion trap MS/MS. Bioanalysis 2011;3:2401-17. [PMID: 22074282 DOI: 10.4155/bio.11.247] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
29 Okano M, Sato M, Kaneko E, Kageyama S. Doping control of biosimilar epoetin kappa and other recombinant erythropoietins after intravenous application: Doping control of epoetin kappa and other recombinant erythropoietins after intravenous application. Drug Test Analysis 2011;3:798-805. [DOI: 10.1002/dta.369] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
30 Davis-Ajami ML, Wu J, Downton K, Ludeman E, Noxon V. Epoetin zeta in the management of anemia associated with chronic kidney disease, differential pharmacology and clinical utility. Biologics 2014;8:155-67. [PMID: 24790409 DOI: 10.2147/BTT.S27578] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
31 Tonia T, Mettler A, Robert N, Schwarzer G, Seidenfeld J, Weingart O, Hyde C, Engert A, Bohlius J. Erythropoietin or darbepoetin for patients with cancer. Cochrane Database Syst Rev 2012;12:CD003407. [PMID: 23235597 DOI: 10.1002/14651858.CD003407.pub5] [Cited by in Crossref: 49] [Cited by in F6Publishing: 50] [Article Influence: 4.9] [Reference Citation Analysis]
32 Reichel C. Detection of peptidic erythropoiesis-stimulating agents in sport. Br J Sports Med 2014;48:842-7. [PMID: 24677025 DOI: 10.1136/bjsports-2014-093555] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
33 Gulácsi L, Brodszky V, Baji P, Rencz F, Péntek M. The Rituximab Biosimilar CT-P10 in Rheumatology and Cancer: A Budget Impact Analysis in 28 European Countries. Adv Ther 2017;34:1128-44. [PMID: 28397080 DOI: 10.1007/s12325-017-0522-y] [Cited by in Crossref: 46] [Cited by in F6Publishing: 41] [Article Influence: 9.2] [Reference Citation Analysis]
34 Taichrib A, Pioch M, Neusüß C. Multivariate statistics for the differentiation of erythropoietin preparations based on intact glycoforms determined by CE-MS. Anal Bioanal Chem 2012;403:797-805. [PMID: 22430131 DOI: 10.1007/s00216-012-5924-8] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
35 Reichel C, Thevis M. Gel electrophoretic methods for the analysis of biosimilar pharmaceuticals using the example of recombinant erythropoietin. Bioanalysis 2013;5:587-602. [PMID: 23425274 DOI: 10.4155/bio.13.9] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
36 Khraishi M, Stead D, Lukas M, Scotte F, Schmid H. Biosimilars: A Multidisciplinary Perspective. Clin Ther. 2016;38:1238-1249. [PMID: 26988243 DOI: 10.1016/j.clinthera.2016.02.023] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 3.7] [Reference Citation Analysis]
37 Jelkmann W, Lundby C. Blood doping and its detection. Blood 2011;118:2395-404. [DOI: 10.1182/blood-2011-02-303271] [Cited by in Crossref: 87] [Cited by in F6Publishing: 78] [Article Influence: 7.9] [Reference Citation Analysis]
38 Kish WS, Sachi H, Naik AD, Roach MK, Bobay BG, Blackburn RK, Menegatti S, Carbonell RG. Design, selection, and development of cyclic peptide ligands for human erythropoietin. Journal of Chromatography A 2017;1500:105-20. [DOI: 10.1016/j.chroma.2017.04.019] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
39 Hlavaty T, Letkovsky J. Biosimilars in the therapy of inflammatory bowel diseases. European Journal of Gastroenterology & Hepatology 2014;26:581-7. [DOI: 10.1097/meg.0000000000000098] [Cited by in Crossref: 26] [Cited by in F6Publishing: 7] [Article Influence: 3.3] [Reference Citation Analysis]
40 Ahmed I, Kaspar B, Sharma U. Biosimilars: Impact of Biologic Product Life Cycle and European Experience on the Regulatory Trajectory in the United States. Clinical Therapeutics 2012;34:400-19. [DOI: 10.1016/j.clinthera.2011.12.005] [Cited by in Crossref: 43] [Cited by in F6Publishing: 37] [Article Influence: 4.3] [Reference Citation Analysis]
41 Gravel P, Naik A, Le Cotonnec J. Biosimilar rhG-CSFs: how similar are they? Targ Oncol 2012;7:3-16. [DOI: 10.1007/s11523-011-0187-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
42 Okano M, Sato M, Kageyama S. Mass spectrometric characterisation of darbepoetin alfa biosimilars with C -terminal arginine residues: Mass spectrometric characterisation of C -terminal arginine NESP. Drug Test Analysis 2016;8:1138-46. [DOI: 10.1002/dta.2102] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
43 Bennett CL, Djulbegovic B, Norris LB, Armitage JO. Colony-stimulating factors for febrile neutropenia during cancer therapy. N Engl J Med. 2013;368:1131-1139. [PMID: 23514290 DOI: 10.1056/nejmct1210890] [Cited by in Crossref: 93] [Cited by in F6Publishing: 46] [Article Influence: 10.3] [Reference Citation Analysis]
44 Danese S, Gomollon F; Governing Board and Operational Board of ECCO. ECCO position statement: the use of biosimilar medicines in the treatment of inflammatory bowel disease (IBD). J Crohns Colitis. 2013;7:586-589. [PMID: 23623738 DOI: 10.1016/j.crohns.2013.03.011] [Cited by in Crossref: 137] [Cited by in F6Publishing: 124] [Article Influence: 15.2] [Reference Citation Analysis]
45 Cornes P. The economic pressures for biosimilar drug use in cancer medicine. Target Oncol 2012;7 Suppl 1:S57-67. [PMID: 22249658 DOI: 10.1007/s11523-011-0196-3] [Cited by in Crossref: 63] [Cited by in F6Publishing: 54] [Article Influence: 6.3] [Reference Citation Analysis]
46 Lakhanpal A, Brahn E. Biosimilars in rheumatic diseases: structural and functional variability that may impact clinical and regulatory decisions. Clin Rheumatol 2016;35:2869-75. [PMID: 27714482 DOI: 10.1007/s10067-016-3430-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
47 Kalantar-Zadeh K. History of Erythropoiesis-Stimulating Agents, the Development of Biosimilars, and the Future of Anemia Treatment in Nephrology. Am J Nephrol 2017;45:235-47. [PMID: 28142147 DOI: 10.1159/000455387] [Cited by in Crossref: 32] [Cited by in F6Publishing: 22] [Article Influence: 6.4] [Reference Citation Analysis]
48 Bennett CL, Chen B, Hermanson T, Wyatt MD, Schulz RM, Georgantopoulos P, Kessler S, Raisch DW, Qureshi ZP, Lu ZK, Love BL, Noxon V, Bobolts L, Armitage M, Bian J, Ray P, Ablin RJ, Hrushesky WJ, Macdougall IC, Sartor O, Armitage JO. Regulatory and clinical considerations for biosimilar oncology drugs. Lancet Oncol 2014;15:e594-605. [PMID: 25456378 DOI: 10.1016/S1470-2045(14)70365-1] [Cited by in Crossref: 82] [Cited by in F6Publishing: 25] [Article Influence: 10.3] [Reference Citation Analysis]
49 Hörl WH. Differentiating factors between erythropoiesis-stimulating agents: an update to selection for anaemia of chronic kidney disease. Drugs 2013;73:117-30. [PMID: 23338536 DOI: 10.1007/s40265-012-0002-2] [Cited by in Crossref: 25] [Cited by in F6Publishing: 19] [Article Influence: 2.8] [Reference Citation Analysis]
50 Ohta S, Yasuno N, Inomoto Y, Matsuda K, Nakagawa Y, Sasagawa I, Tanaka M. Efficacy of once or twice weekly administration of epoetin κ in patients receiving hemodialysis: A retrospective study. Exp Ther Med 2014;7:27-30. [PMID: 24348759 DOI: 10.3892/etm.2013.1384] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
51 Jelkmann W. Biosimilar recombinant human erythropoietins ("epoetins") and future erythropoiesis-stimulating treatments. Expert Opin Biol Ther 2012;12:581-92. [PMID: 22471247 DOI: 10.1517/14712598.2012.672968] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
52 Azevedo VF, Galli N, Kleinfelder A, D'Ippolito J, Urbano PC. Etanercept biosimilars. Rheumatol Int 2015;35:197-209. [PMID: 24980068 DOI: 10.1007/s00296-014-3080-5] [Cited by in Crossref: 40] [Cited by in F6Publishing: 31] [Article Influence: 5.0] [Reference Citation Analysis]
53 Han H, Lee J, Shin D, Shin KH, Jeon H, Lim KS, Yoon SH, Shin SG, Jang IJ, Cho JY, Yu KS. Pharmacodynamics, pharmacokinetics, and tolerability of intravenous or subcutaneous GC1113, a novel erythropoiesis-stimulating agent. Clin Drug Investig 2014;34:373-82. [PMID: 24623104 DOI: 10.1007/s40261-014-0183-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
54 Zinzani PL, Dreyling M, Gradishar W, Andre M, Esteva FJ, Boulos S, González Barca E, Curigliano G. Are Biosimilars the Future of Oncology and Haematology? Drugs 2019;79:1609-24. [PMID: 31541401 DOI: 10.1007/s40265-019-01193-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
55 Abraham I, Han L, Sun D, MacDonald K, Aapro M. Cost savings from anemia management with biosimilar epoetin alfa and increased access to targeted antineoplastic treatment: a simulation for the EU G5 countries. Future Oncol 2014;10:1599-609. [PMID: 25145430 DOI: 10.2217/fon.14.43] [Cited by in Crossref: 37] [Cited by in F6Publishing: 36] [Article Influence: 5.3] [Reference Citation Analysis]
56 Lahiff C, Kane S, Moss AC. Drug development in inflammatory bowel disease: The role of the FDA: . Inflammatory Bowel Diseases 2011;17:2585-93. [DOI: 10.1002/ibd.21712] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
57 Rinaudo-gaujous M, Paul S, Tedesco ED, Genin C, Roblin X, Peyrin-biroulet L. Review article: biosimilars are the next generation of drugs for liver and gastrointestinal diseases. Aliment Pharmacol Ther 2013;38:914-24. [DOI: 10.1111/apt.12477] [Cited by in Crossref: 41] [Cited by in F6Publishing: 36] [Article Influence: 4.6] [Reference Citation Analysis]
58 Renner P, Milazzo S, Liu JP, Zwahlen M, Birkmann J, Horneber M. Primary prophylactic colony-stimulating factors for the prevention of chemotherapy-induced febrile neutropenia in breast cancer patients. Cochrane Database Syst Rev 2012;10:CD007913. [PMID: 23076939 DOI: 10.1002/14651858.CD007913.pub2] [Cited by in Crossref: 13] [Cited by in F6Publishing: 28] [Article Influence: 1.3] [Reference Citation Analysis]
59 Madeddu C, Gramignano G, Astara G, Demontis R, Sanna E, Atzeni V, Macciò A. Pathogenesis and Treatment Options of Cancer Related Anemia: Perspective for a Targeted Mechanism-Based Approach. Front Physiol 2018;9:1294. [PMID: 30294279 DOI: 10.3389/fphys.2018.01294] [Cited by in Crossref: 38] [Cited by in F6Publishing: 35] [Article Influence: 9.5] [Reference Citation Analysis]
60 Abraham J. Developing oncology biosimilars: an essential approach for the future. Semin Oncol. 2013;40 Suppl 1:S5-24. [PMID: 24267944 DOI: 10.1053/j.seminoncol.2013.09.015] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 2.1] [Reference Citation Analysis]
61 Farhat F, Torres A, Park W, de Lima Lopes G, Mudad R, Ikpeazu C, Abi Aad S. The Concept of Biosimilars: From Characterization to Evolution-A Narrative Review. Oncologist 2018;23:346-52. [PMID: 29284760 DOI: 10.1634/theoncologist.2017-0126] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]